Johns Hopkins University owns the patent for the PI3K biomarker and has previously granted an exclusive license to Qiagen’s wholly owned subsidiary DxS, presently Qiagen Manchester. Qiagen said
DuoCap is a single oral dosage unit that comprises a capsule-in-a-capsule and offers therapeutic applications. Encap claimed that the patented Duocap technology can provide protection for clients interested
RXi Pharma is expected to use the fund for pre-clinical development of RNAi therapeutics using its novel, proprietary therapeutic platform, which includes both novel RNAi compounds and advanced
With acquisition, A5 Labs has established the capacity for contract analytical, product development, regulatory and testing services in the pharmaceutical and environmental sector. Richard Azani, president and CEO
Cogenzia is Innocoll’s topical antibiotic therapy for the adjuvant treatment of infected diabetic foot ulcers. Patients with a moderate or severe diabetic foot infection will be treated in
The KCI ART is expected to investigate emerging medical therapies and technologies to fuel product development and commercialisation. The ART will focus on conducting applied research to develop
The agreement specifies exclusivity for the products for the institutional / healthcare market and includes an adult incontinence cream, skin barrier cream and super moisturizer. The agreement specifies
Following the acquisition, R5 is expected to retain its current identity and brand and will become a subsidiary of Aesica Pharmaceuticals. Aesica Pharma said that the capability and
Fredericksburg said that the trial, supported by the National Cancer Institute (NCI) to evaluate treatment for metastatic (advanced stage) melanoma, is expected to enroll 148 patients across the
The new relationship includes a series of four functional confection mixes that will incorporate GanedenBC30. Ganeden Biotech claims that GanedenBC30 has an ability to survive harsh manufacturing processes,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.